Rice Partnership LLC increased its holdings in Danaher Corporation (NYSE:DHR – Free Report) by 42.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,210 shares of the conglomerate’s stock after acquiring an additional 11,439 shares during the period. Danaher comprises approximately 1.2% of Rice Partnership LLC’s portfolio, making the stock its 22nd biggest holding. Rice Partnership LLC’s holdings in Danaher were worth $8,747,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. JPL Wealth Management LLC bought a new position in shares of Danaher in the third quarter valued at approximately $25,000. Elevated Capital Advisors LLC bought a new position in shares of Danaher in the fourth quarter valued at approximately $26,000. WFA of San Diego LLC bought a new position in shares of Danaher in the second quarter valued at approximately $26,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Danaher in the third quarter valued at approximately $27,000. Finally, Financial Life Planners bought a new position in Danaher during the third quarter valued at $32,000. 79.05% of the stock is owned by institutional investors.
Danaher Price Performance
Danaher stock opened at $175.97 on Wednesday. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The business has a fifty day moving average price of $181.91 and a 200-day moving average price of $207.20. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52. The firm has a market capitalization of $124.54 billion, a P/E ratio of 34.04, a PEG ratio of 2.40 and a beta of 0.81.
Danaher Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s dividend payout ratio (DPR) is presently 30.95%.
Analyst Upgrades and Downgrades
DHR has been the subject of several research reports. JPMorgan Chase & Co. reduced their price objective on Danaher from $275.00 to $245.00 and set an “overweight” rating for the company in a report on Wednesday, April 22nd. UBS Group reduced their price objective on Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Evercore increased their price objective on Danaher from $225.00 to $232.00 and gave the company an “outperform” rating in a report on Tuesday, April 21st. TD Cowen reduced their price objective on Danaher from $245.00 to $240.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Finally, Wells Fargo & Company reduced their price objective on Danaher from $240.00 to $212.00 and set an “equal weight” rating for the company in a report on Wednesday, April 22nd. Nineteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $238.24.
Check Out Our Latest Analysis on DHR
Danaher News Summary
Here are the key news stories impacting Danaher this week:
- Positive Sentiment: Danaher’s SCIEX unit introduced new product and software updates at ASMS, including the novus V55 system with SCIEX OS 5.0 and AI enablement tools, plus broader ZenoTOF platform expansions. These launches suggest continued innovation and support Danaher’s life sciences growth story. Article: SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement Tools
- Positive Sentiment: The SCIEX ZenoTOF platform updates and collaborations could improve workflow efficiency and strengthen Danaher’s competitive position in advanced analytical instruments. Article: SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations
- Neutral Sentiment: Recent commentary is focused on whether Danaher stock has become more attractive after its pullback, but the article frames this as a valuation debate rather than a clear catalyst. Article: Is It Time To Reassess Danaher (DHR) After Its Recent Share Price Weakness?
- Neutral Sentiment: A broader healthcare valuation piece highlighted large-cap healthcare stocks with expensive valuations, which may keep pressure on sentiment for Danaher if investors remain focused on multiples. Article: These 10 large-cap US healthcare companies carry the market’s most expensive valuations
About Danaher
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Featured Stories
- Five stocks we like better than Danaher
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
